A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Not all companies are created equal, and StockStory is here to surface the ones with real upside. That said, here are three cash-producing companies to avoid and some better opportunities instead.
Qorvo (QRVO)
Trailing 12-Month Free Cash Flow Margin: 17.8%
Formed by the merger of TriQuint and RF Micro Devices, Qorvo (NASDAQ: QRVO) is a designer and manufacturer of RF chips used in almost all smartphones globally, along with a variety of chips used in networking equipment and infrastructure.
Why Are We Bearish on QRVO?
- Annual sales declines of 4.6% for the past two years show its products and services struggled to connect with the market during this cycle
- Sales are projected to tank by 1.5% over the next 12 months as its demand continues evaporating
- Earnings per share decreased by more than its revenue over the last five years, showing each sale was less profitable
At $116.13 per share, Qorvo trades at 15.6x forward P/E. To fully understand why you should be careful with QRVO, check out our full research report (it’s free).
Boston Beer (SAM)
Trailing 12-Month Free Cash Flow Margin: 10.7%
Known for its flavorful beverages challenging the status quo, Boston Beer (NYSE: SAM) is a pioneer in craft brewing and a symbol of American innovation in the alcoholic beverage industry.
Why Should You Sell SAM?
- Products aren’t resonating with the market as its revenue declined by 2.2% annually over the last three years
- Operating profits fell over the last year as its sales dropped and it struggled to adjust its fixed costs
- Below-average returns on capital indicate management struggled to find compelling investment opportunities, and its decreasing returns suggest its historical profit centers are aging
Boston Beer is trading at $171.46 per share, or 17.6x forward P/E. Dive into our free research report to see why there are better opportunities than SAM.
USANA (USNA)
Trailing 12-Month Free Cash Flow Margin: 1.7%
Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE: USNA) manufactures and sells nutritional, personal care, and skincare products.
Why Does USNA Give Us Pause?
- Annual sales declines of 1.2% for the past three years show its products struggled to connect with the market
- Subscale operations are evident in its revenue base of $913.4 million, meaning it has fewer distribution channels than its larger rivals
- Performance over the past three years shows each sale was less profitable as its earnings per share dropped by 32.9% annually, worse than its revenue
USANA’s stock price of $14.16 implies a valuation ratio of 14.1x forward P/E. If you’re considering USNA for your portfolio, see our FREE research report to learn more.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
